A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Naproxen Oral

Naproxen Oral reduces pain, inflammation, and fever by inhibiting prostaglandin synthesis.

First FDA approval2021-03-12
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.165/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.165
Across all dosage forms in distribution.
Highest NADAC
$0.165
Range is tight.
Plans with PA
6 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema6 entries indexed · 4 visible
What is Naproxen Oral used for?

Naproxen Oral reduces pain, inflammation, and fever by inhibiting prostaglandin synthesis.

Is there a generic for Naproxen Oral?

No. Naproxen Oral is brand-only with no generic equivalents currently in market.

How much does my plan pay for Naproxen Oral?

Across 329 Part D plans, Naproxen Oral averages $0.165/unit (NADAC). Lowest available: $0.165/unit. Highest in distribution: $0.165/unit.

Is Naproxen Oral on the FDA shortage list?

No. Naproxen Oral is not currently on the FDA Drug Shortage Database.

2 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.